Tenderwize
Back to tender search

Non-exclusive drug discount agreement for Lipegfilgrastim

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2028 · 617 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lipegfilgrastim (ATC-Code nach WHO: L03AA14)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

Open house may be terminated early if exclusive discount agreements are concluded (typically 8-12 months after publicat...

No guaranteed demand – volumes depend on prescription behavior, patient numbers, and pharmacy stocking.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive discount agreements for Lipegfilgrastim under §130a SGB V
  • Open-house model with ongoing submissions
Show full summary

Open-house model for non-exclusive drug discount agreements under §130a SGB V for Lipegfilgrastim (ATC L03AA14). Published for transparency, not a public procurement. No guaranteed volumes, no exclusivity. Eligible pharmaceutical entrepreneurs can participate by submitting via DTVP periodically until 30 April 2028.

Risks

Open house may be terminated early if exclusive discount agreements are concluded (typically 8-12 months after publicat...

No guaranteed demand – volumes depend on prescription behavior, patient numbers, and pharmacy stocking.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs.18 AMG

Eligibility

  • Submit declarations: exclusion grounds and Russia sanctions

Administrative

  • Confidentiality of all procurement documents and discount rates

Requirements may be incomplete.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Lipegfilgrastim

Open-house model for non-exclusive discount agreements for Lipegfilgrastim. No minimum purchase quantities. Confidentiality required.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Apr 2026 - Apr 2028

Category

Pharmaceutical products

Deadline

Deadline Apr 30, 2028

Procurement Details

Publication date
25 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
136678-2026

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3